ArcticZymes Technologies ASA announces that Salt Active Nuclease High Quality GMP grade (SAN HQ GMP) has passed the DMF filing Type II with the US Food and Drug Administration (FDA) and has received the acknowledgement letter with the Master File number 29754 as a reference. This means that ArcticZymes can provide its customers with a Letter of Authorization (LoA) for their product registrations with the US FDA upon request. AZT anticipates commercial launch of SAN HQ GMP in Fourth Quarter 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.9 NOK | -.--% | -0.96% | -38.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.33% | 119M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- AZT Stock
- News ArcticZymes Technologies ASA
- ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDA